U.S. pharma giant copyright scrapped two experimental weight loss products past yr—a once-every day tablet, lotiglipron, because of elevated liver enzymes along with a two times-everyday tablet, danuglipron, as a result of strong Uncomfortable side effects—but CEO Albert Bourla has e